Singapore’s Health Sciences Authority (HSA) and Japan’s Ministry of Health, Labour and Welfare (MHLW) signed a Memorandum of Cooperation in Tokyo on April 20, 2026. The agreement aims to bring the two regulators closer together in how they oversee drug products. At its core, the goal is to help patients get timely access to safe and effective medicines.
The two sides plan to work together in several practical areas. These include reliance pathways for product approvals, cooperation on Good Manufacturing Practice (GMP) inspections, and sharing updates on new and emerging technologies. The agreement also encourages more joint work in regional and international initiatives.
A key focus is on reducing duplicate GMP inspections. Under the new arrangement, both countries may rely on each other’s inspection outcomes. This could lower the burden on manufacturers and shorten approval timelines. In some cases, access to medicines could improve by a few months, while safety standards remain unchanged.
The cooperation will cover the full product lifecycle, which includes clinical trials, product registration, manufacturing, and post-market monitoring. The agreement builds on earlier collaboration between the two countries and reflects a continued effort to make regulatory processes more efficient while supporting innovation.
Written by: Ames Gross – President and Founder, Pacific Bridge Medical (PBM)
Mr. Gross founded PBM in 1988 and has helped hundreds of medical companies with regulatory and business development issues in Asia. He is recognized nationally and internationally as a leader in the Asian medical markets. Mr. Gross has a BA degree, Phi Beta Kappa, from the University of Pennsylvania and an MBA from Columbia University.